Oric Pharmaceuticals initiates Himalayas-1 Phase 3 trial of rinzimetostat plus darolutamide in mCRPC
Reuters2026/08/03 20:23- Oric Pharmaceuticals initiated Himalayas-1, a global Phase 3 registrational trial of rinzimetostat in metastatic castration-resistant prostate cancer previously treated with abiraterone.
- Study will test rinzimetostat with Bayer’s NUBEQA (darolutamide) versus physician’s choice of an AR inhibitor or docetaxel, targeting delayed disease worsening.
- Bayer will supply darolutamide at no cost; Oric retains full global development and commercial rights to rinzimetostat.
- Rinzimetostat program update is expected in 2H 2026; no new clinical results were reported in the filing.
- Cash and investments totaled $387.6 million as of June 30, 2026; runway forecast into 2H 2028, beyond the first Phase 3 readout.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Ivy League’s space gamble: Harvard reveals $2.2 billions SpaceX position, its largest single stock holding
Harvard University Investment Management Company disclosed that it holds $2.2 billion worth of SpaceX shares, making it the largest single stock position in its $4.3 billion US equity portfolio. This holding originated from Harvard’s early investment in SpaceX through venture capital funds, and the position has significantly appreciated after SpaceX’s public listing in June this year. The University of California also disclosed a roughly $1 billion position in SpaceX during the same period. Over the past decade, endowment funds from several universities have made substantial bets on private tech assets.
Circle obtains Major Payment Institution license in Singapore
Crypto prices
More
